ITOG Selumetinib Trial Achieves Accrual Goal!
ITOG Selumetinib Trial Achieves Accrual Goal!
Congratulations to Principal Investigator: Alan Ho, MD at Memorial Sloan-Kettering Cancer Center and his team for achieving accrual goal of 60 for the Selumetnib plus RAI for RAI-Avid Thyroid Cancer.
Recent Posts
Catch up on the latest from ITOG—research progress, community updates, and highlights shaping the future of thyroid [...]
2024 Robert F. Gagel ITOG Discovery Award Winner: Jim Fagin, MD for “Leveraging therapeutic vulnerabilities induced by [...]
